ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Esophageal Cancer - Multimodality Therapy

November 16, 2014
This article systematically reviewed the impact of surgical adverse events (SAEs) on quality of life after major GI surgery.  The mean difference in QOL between pts with and without SAEs was highest for esophagectomy (0.14; scale 0 to 1), while results for antireflux surgery were mixed. 
November 11, 2014
This study explored financial conflicts of interest (FCOI) among authors of published guidelines and consensus statements and their relationship to endorsement of specific drugs.  93% of recent articles reported FCOI status.  Of articles publishing funding sources, 65% reported partial or full industry funding.  Endorsement of chemotherapeutic agents
October 8, 2014
This multicenter prospective trial evaluated the impact of induction therapy on anastomotic leak (AL) and other complications after esophagectomy.  Of 2944 included pts, 593 had induction chemoradiotherapy.  AL occurred in 8.8% of induction therapy pts compared to 10.6% of surgery only patients.  90 day postoperative morbidity and mortality rates wer
October 8, 2014
It has recently been reported that a longer interval to esophagectomy following induction therapy results in higher pathologic response rates.  The current study used data from the CROSS trial to determine whether a longer interval to esophagectomy following induction therapy results in improved survival.  Time to surgery (TTS) was a median of 48 day
September 25, 2014
This retrospective review evaluated the relationship of pretreatment vs post-induction therapy stage to survival in patients undergoing surgery for esophageal adenocarcinoma in 2 centers in London.  Among 584 pts, 400 underwent induction therapy.  Downstaging predicted improved survival (HR 0.43).  Downstaging was associated with decreased rates of l
September 16, 2014
This retrospective study evaluated recurrence patterns and management of recurrence after bimodality (chemoradiotherapy) for esophageal cancer in 276 pts.  Local relapse alone developed in 23%, and 36% of those patients had salvage esophagectomy.  Median survival for those undergoing salvage esophagectomy was 59 mos, whereas pts who were not offered
August 9, 2014
This randomized trial involving 30 centers in France compared outcomes after induction chemoradiotherapy followed by resection to resection alone for stage I or II esophageal cancer.  The R0 resection rate was similar between the groups.  Postoperative mortality was higher in the induction therapy group (11.1% vs 3.4%).  Long-term survival was simila
July 29, 2014
Using data from 2 centers in London, outcomes after induction therapy and resection for esophageal cancer were analyzed according to the pathological response to induction therapy.  Downstaging was the strongest predictor of survival (HR 0.43).  Downstaging was also associated with a lower rate of local recurrence (6% vs 13%) and systemic recurrence
July 28, 2014
The efficacy of induction therapy for clinical T2 esophageal cancer was evaluated using the National Cancer Database.  Pretreatment staging was accurate in only 27% of pts.  42% of pts were upstaged and 32% were downstaged.  Induction therapy had no survival benefit.   
July 1, 2014
In this randomized trial involving195 pts from 30 centers, pts underwent chemoradiotherapy followed by surgery or surgery alone for stage I or II esophageal cancer.  The median follow-up was 94 months.  80% of pts had clinical stage II disease.  R0 resection rate and 3-year survival were similar between the groups.  Induction therapy was associated w

Pages